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ABSTRACT We have used in vitro deletion mutagenesis in
combination with DNA transfection to search for cis-acting
regulatory elements involved in the tissue-specific expression of
a human class H major histocompatibility complex gene. A
140-base-pair 5' flanking fragment that contains the class II
box consensus sequences and an octamer sequence (AT-
TTGCAT) confers tissue specificity on the promoter of the
HLA-DRx gene. Recombinant DNA plasmids containing this
DRa gene segment fused to the coding sequence of the bacterial
chloramphenicol acetyltransferase gene are expressed at higher
levels in human B-cell lines than in human T-cell lines. We have
demonstrated that the most 5' of the class II boxes is essential
for tissue-specific DRa promoter function. In addition, using
an electrophoretic mobility shift assay to identify DNA binding
proteins, we have detected binding of nuclear proteins to DNA
probes containing the class II boxes and the octamer sequence.
A protein that binds to the octamer is present at higher levels
in nuclear extracts of B-cell lines than in other cell lines
examined. This protein may be important for the tissue-specific
expression of the HLA-DRx gene.
Class II major histocompatibility complex (MHC) antigens
are cell-surface glycoproteins that function in immune cell-
cell recognition and interaction. These molecules control the
level of immune response to certain antigens through their
role in the presentation of antigen to class II-restricted,
antigen-specific T cells (1). There are at least three human
class II antigens, designated DR, DP, and DQ. All class II
molecules are composed of two noncovalently associated
subunits. The heavy (a) chain is relatively nonpolymorphic,
and the light (,B) chain is highly polymorphic.
The genes coding for the class II MHC antigens are
transcribed in a tissue-specific manner (2). Class II antigens
are found primarily on certain cells of the immune system,
including B lymphocytes, macrophages, and some activated
T cells (3). Class II gene expression is differentially regulated
in different cell types and is responsive to multiple regulators
(4). For example, class II antigen expression on B cells is
modulated by B-cell growth factor (5), whereas that on
macrophages is modulated by y-interferon, a-fetoprotein,
and prostaglandin E (4). y-Interferon can enhance or induce
the expression of class II genes in many different cell types,
including some nonlymphoid cells (6).
A few studies have employed gene transfer experiments
and sequence homology searches to identify cis-acting tran-
scriptional regulatory elements in class II genes. Gene
transfer experiments have demonstrated that a B-lympho-
cyte-specific enhancer element is located in a 2.0-kilobase
(kb) 5' flanking fragment of the mouse Edp gene (7). Our
laboratory has identified a region in the 5' flanking sequence
of the HLA-DRa gene that is important for vinterferon
induction of class II antigens in human glioma (8) and
melanoma (unpublished results) cell lines. In a similar study,
another laboratory has characterized DNA elements that are
involved in the y-interferon induction of the HLA-DQ2A3 gene
in human fibroblasts (9). A distinct consensus sequence for
a-interferon induction is located further upstream from the
cap site than the v-interferon response sequence in HLA
class II genes (10).
Sequence homology searches have revealed that human
and murine class II a- and A-chain genes possess two short
conserved sequences positioned at a distance of 100-150 base
pairs (bp) on the 5' side of the ATG start codon for translation
(11). These consensus sequences, referred to as class II
boxes, are possibly involved in the regulation of class II gene
expression. In addition, an octanucleotide sequence that is
found '70 bp upstream from the site of transcriptional
initiation in all immunoglobulin light- and heavy-chain genes
is also found :40 bp upstream from the cap site in the
HLA-DRa gene (12). This octamer sequence is required for
tissue-specific expression of immunoglobulin genes (13-15).
In this report, we investigate the cis-actingDNA sequences
that control tissue-specific expression of class II genes. To do
this, we have transfected a set of recombinant plasmids
containing 5' promoter deletions of the HLA-DRa gene fused
to a bacterial indicator gene into human B- and T-cell lines.
We then assayed extracts of transfected cells for DRa-
controlled transient expression of the indicator gene. We
have also used an electrophoretic mobility shift assay to
detect specific binding of nuclear proteins to DNA fragments
containing the class II boxes and the octamer.
MATERIALS AND METHODS
Plasmids. pSV2CAT is identical to the plasmid described
by Gorman et al. (16). DNA constructs containing 5' flanking
sequences of the HLA-DRa gene fused to the bacterial
chloramphenicol acetyltransferase (CAT) gene are described
in detail in ref. 8. In brief, pD164-2 is the parental plasmid
containing the CAT gene but no DRa sequences; pDR1000
contains - 1000 bp ofDNA 5' to the cap site, the cap site, and
30 bp 3' to the cap site of the DRa gene; and pDR300 is
identical to pDR1000 but contains "300 bp ofDNA 5' to the
cap site. Additional deletion mutants were prepared as
follows: pDRA1000, which contains 1000 bp of DRa 5'
flanking sequences (described in ref. 8), was linearized with
Xba I; this was followed by exonuclease III (Stratagene, San
Diego, CA) digestion for 1.5-3.0 min at 26°C. Single-stranded
DNA was removed with mung bean nuclease (Stratagene);
this was followed by digestion with Cla I, treatment with
Klenow enzyme to form blunt ends, and religation. The
deletion mutants were characterized by dideoxy DNA se-
quence determination directly from the double-stranded
plasmid DNA (17), using a 20-base single-stranded oligonu-
Abbreviations: CAT, chloramphenicol acetyltransferase; MHC, ma-
jor histocompatibility complex.
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cleotide (prepared by C. Hutchison, University of North
Carolina, Chapel Hill) complementary to a 5' CAT coding
sequence (18) as a primer for reverse transcriptase. The 5'
deletion mutants designated 5' A-109, 5' A-91, and 5' A-53
containDRa sequences extending from positions 109, 91, and
53 bp upstream from the cap site to +30 bp (see Fig. 1).
Cell Lines. Raji is a human Epstein-Barr virus (EBV)-
positive Burkitt lymphoma cell line; Ramos RA 1 is a human
EBV-negative Burkitt lymphoma cell line; 721.174 is a human
B-lymphoblastoid cell line (kindly provided by Robert
DeMars, University of Wisconsin, Madison); HSB and H9
are human T-leukemia cell lines; and HeLa is a human
cervical carcinoma cell line.
Transfection and CAT Assay. Suspension cultures of hu-
man lymphoblastoid cell lines were transfected using DEAE-
dextran (19). Cells (107) were suspended in 2 ml of a
transfection cocktail containing 10 ,ug of plasmid DNA and
500 Ag of DEAE-dextran (Pharmacia, average M, 500,000).
After 1 hr at 370C, the cells were washed twice with
serum-free medium and resuspended in 10 ml of complete
medium. Approximately 48 hr following transfection, cells
were harvested by centrifugation, washed once with phos-
phate-buffered saline, and resuspended at 50 t1d per 106 cells
in 0.25 M Tris HCl (pH 7.6). Cells were lysed by several
freeze-thaw cycles or by sonication, cellular debris was
removed by centrifugation, and the resulting extracts were
assayed for CAT activity as described (16). Reaction mix-
tures contained 25 ,ud of cellular extract, 0.175 M Tris HCl
(pH 7.6), 1 mM acetyl-CoA, and 0.1 ,uCi (1 Ci = 37 GBq) of
[14C]chloramphenicol (New England Nuclear; specific activ-
ity, 55 mCi/mmol) in a total volume of 180 ,u. In general, the
incubation time was several hours.
Electrophoretic Mobility Shift Assay. This procedure is
described in refs. 20-22 and in modified form in ref. 23.
Nuclear extracts employed in this assay were prepared
according to the protocol ofDignam et al. (24) and contained
2-6 mg of protein per ml as assayed by the Bradford
dye-binding method (25). Binding reactions contained 25 mM
Hepes (pH 7.9), 2.5 mM MgCl2, 25 mM NaCl, 4 ,ug of
poly(dI-dC)'poly(dI-dC) (Pharmacia), 6 tkg of nuclear extract
protein, and typically 100,000 cpm (0.5 ng) of end-labeled
DNA fragment in a total volume of 20 t1d. After a 30-min
incubation at room temperature, the samples were electro-
phoresed through a low ionic strength 8% polyacrylamide gel
(acryl:bis weight ratio of 29:1) containing 6.7 mM Tris HCl
(pH 7.5), 3.3 mM sodium acetate, and 1 mM Na2EDTA. The
gel was preelectrophoresed for 2 hr at 20 mA and electro-
phoresed for 2-3 hr at the same current with buffer recircula-
tion. The wet gel was autoradiographed at -70°C with
intensifying screens. Two synthetic double-stranded oligo-
Q 3ah
nucleotides (prepared by C. Hutchison, University of North
Carolina, Chapel Hill) were used as probes in the binding
reactions (see Fig. 1). These DNA fragments were end-
labeled using [y-32P]ATP and T4 polynucleotide kinase
(Bethesda Research Laboratories) (26). Labeled fragments
were separated from unincorporated radionucleotide by pas-
sage over a NENSORB 20 nucleic acid purification cartridge
(New England Nuclear).
Methylation Interference Analysis. This procedure was
performed exactly as described in ref. 27, except that DNA
was isolated from mobility shift gels by overnight agitation of
the crushed gel slices in 0.5 M ammonium acetate. Products
of the piperidine cleavage reactions were analyzed by elec-
trophoresis through a 12% polyacrylamide/8 M urea se-
quencing gel.
RESULTS
A 140-bp 5' Flanking Region Confers Tissue Specificity on
the Promoter of the HLA-DRa Gene. The 5' flanking regions
of many genes contain important transcriptional regulatory
elements (28). For this reason, we initiated our search for
DNA sequences involved in the tissue-specific expression of
the HLA-DRa gene with a 1000-bp 5' flanking fragment. We
fused this DNA fragment to the CAT gene and transfected the
resulting recombinant into human B- and T-lymphoblastoid
cell lines. Although a detectable level of CAT activity was
observed in T cells, much higher levels were consistently
observed in B cells, in accord with the tissue-specific expres-
sion of the DRAa gene by these cell types (Fig. 2, lanes 3 and
7). A deletion mutant containing 300 bp of 5' flanking
sequence yielded similar results (Fig. 2, lanes 4 and 8), except
that CAT activity was greater in B cells transfected with
pDR300 than with pDR1000. This latter observation suggests
the presence of a negative regulatory element in the addi-
tional 700 bp of DNA contained in pDR1000. Transfection
results similar to those for T cells were observed for HeLa
cells (data not shown). Quantitation of plasmid DNA in Hirt
supernatants (29) of transfected cells confirmed that the
difference in CAT activity in B and T cells was not due to a
simple difference in transfection efficiency of the two cell
types.
To more precisely define the location of DNA sequences
involved in the tissue-specific expression of the HLA-DRa
gene, we prepared a progressive series of deletion mutants
using exonuclease III. Expression of CAT in B cells was still
observed with a mutant (Fig. 1, 5' A-109) containing only 140
bp of DRa sequence (Fig. 3, lane 5). This DNA fragment
contains the class II boxes and the immunoglobulin octamer
motif. The decrease in promoter activity observed with this
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FIG. 1. Regulatory elements in the promoter region of the HLA-DRa gene. Nucleotides are numbered relative to the cap site. Potential
cis-acting transcriptional regulatory elements include the class II boxes (designated consensus A and consensus B), the octamer motif
A IrTGCAT, a CAAT-type sequence, and a "TATA box." The "CAAT box" specified in the figure is not in good agreement with the consensus
sequence for CAAT boxes. A perfect "CCAAT box" is located on the opposite strand of the consensus B sequence. The 5' deletion mutants
used in transfection analyses contained DRa sequences extending from positions indicated by arrows to +30 bp. Locations of 45-bp and 50-bp
oligonucleotides used as probes in protein-DNA-binding assays are shown below the sequence.
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FIG. 2. Transfection of human B cells (B) and T cells (T) with
DRa-CAT recombinants. Raji and H9 cells were transfected using
DEAE-dextran. Extracts of transfected cells were analyzed for CAT
activity by thin-layer chromatography and autoradiography. The
autoradiograph shows relative amounts of acetylated chloramphen-
icol reaction products. pSV2CAT was used as a positive control to
show that Raji and H9 cells transfect with approximately equal
efficiency (lanes 1 and 5). The negative control was pD164-2, which
contains CAT coding sequences but no DRa sequences (lanes 2 and
6) (8). pDR1000 and pDR300 contain "1000 bp and -300 bp,
respectively, of DRa 5' flanking sequence (8). Lane 9, reaction
products obtained using a commercial preparation of bacterial CAT.
deletion mutant is probably due to the removal of some
sequences important for DRa expression that are located 5'
of the class II boxes. Deletion of the class II box most 5' to
the cap site (deletion mutant 5' A-91) abolished the activity of
the DRa promoter in our assay system, suggesting that this
DNA sequence is an essential cis-acting transcriptional
regulatory element in the DRa gene (Fig. 3, lane 6). In a
predictable fashion, deletion of both class II boxes (deletion
mutant 5' A-53) also destroyed DRa promoter activity (Fig.
3, lane 7).
A Protein in B-Cell Nuclear Extracts Binds to the HLA-DRa
Gene Promoter Region. The high degree of sequence and
positional conservation of the class II boxes, in combination
with their functional requirement in DRa gene expression (as
indicated by our transfection data), suggests that these DNA
sequences may interact with sequence-specific transcription
factors. We were also interested in looking for specific
protein interactions with the octamer motif located in the
DRa promoter, due to recent reports of nuclear factors
binding to this sequence in immunoglobulin genes (23, 27,
30). We were particularly interested in nuclear factors spe-
cific to B cells, since these factors could be involved in the
tissue-specific expression of the DRa gene. To this end, we
have used an electrophoretic mobility shift assay to identify
DNA-binding proteins. This assay is based on the retarded
migration of protein-DNA complexes relative to free DNA
during gel electrophoresis. Since the use of small DNA
fragments as probes enhances the sensitivity of the assay
(23), we began our studies with a 45-bp synthetic oligonu-
cleotide that contains one of the class II boxes (consensus B)
and the octamer motif (Fig. 1). When we used the labeled
45-bp oligonucleotide as a probe in the mobility shift assay,
we observed that several DNA-protein complexes were
formed (Fig. 4). All nuclear extracts tested displayed a band,
B1, which is most likely generated by a previously described
ubiquitous octamer-specific DNA-binding protein (23). Of
primary interest is a band, B2, migrating faster than B1,
which is most intense in binding reactions containing nuclear
extracts of B-cell lines. This complex is much less abundant,
if present at all, in binding reactions containing nuclear
extracts of T-cell lines and HeLa cells.
The B-Cell Nuclear Factor Is an Octamer-Binding Protein.
To establish the specificity and the site of the DNA-protein
interaction in B2, a binding competition analysis was per-
formed. The 45-bp oligonucleotide containing the consensus
B sequence and the octamer, a 50-bp oligonucleotide con-
taining consensus A and consensus B sequences (see Fig. 1),
and a 27-bp oligonucleotide of unrelated sequence were used
as unlabeled competitors in the mobility shift assay. The
results of this experiment are shown in Fig. 5.
The 45-bp oligonucleotide that contains the octamer se-
quence competes in the formation of B1 and B2 (lane 4). In
contrast, the 50-bp class II box-containing oligonucleotide
and the unrelated 27-bp oligonucleotide do not affect the
formation of either complex. Hence, only an octamer-
containing competitor has an effect on the formation of
protein complexes with a DNA probe that contains the
octamer sequence and one class II box. These data strongly
suggest that the factors involved in the formation of B1 and
B2 are octamer-specific proteins. Further support for this
conclusion was obtained by employing the 50-bp oligonucle-
otide that contains both class II boxes as a probe in the
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FIG. 3. Transfection of human B cells with deletion mutants.
Autoradiograph of CAT assay on extracts of Raji cells transfected
with a progressive series of DRa deletion mutants. Lane 1, pSV2-
CAT used as a positive control; lane 2, negative control; lane 3,
plasmid contains 1000 bp of DRa 5' flanking sequence; lane 4,
plasmid contains 300 bp of DRa 5' flanking sequence; lanes 5-7,
deletion mutants as shown in Fig. 1.
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FIG. 4. Electrophoretic mobil-
ity shift assays of nuclear extracts
from human B, T, and HeLa cells.
A 45-bp oligonucleotide contain-
ing one of the class II boxes and
the octamer motif (see Fig. 1) was
used as a probe in the binding
assay. Protein-DNA complexes
were electrophoresed through an
8% polyacrylamide gel. The nucle-
ar extracts were prepared from the
following cell lines: Raji (lane 1),
721.174 (lane 2), Ramos RA 1 (lane
3), HSB (lane 4), H9 (lane 5), and
HeLa (lane 6). B1, position of a
complex generated by a nuclear
factor(s) present in all cell types
examined; B2, a complex generat-
ed by a factor(s) most abundant in
B cells; F, free probe.
'4
:~j..
Proc. Natl. Acad Sci. USA 84 (1987)
Proc. Nati. Acad. Sci. USA 84 (1987) 4257
binding assay. We do not detect any complexes exhibiting
B-cell specificity with this probe (Fig. 5, lane 9). We do detect
one complex that migrates with a mobility similar to B1 in all
of the extracts tested. Competition analysis suggests that this
complex results from a specific interaction between the class
II boxes and a nuclear protein; the 45-bp oligonucleotide and
the 50-bp oligonucleotide compete in the formation of this
complex (Fig. 5, lanes 10 and 11), whereas the unrelated
27-bp oligonucleotide does not (Fig. 5, lane 12).
As a final proof that the nuclear factors involved in the
formation of B1 and B2 are octamer-binding proteins, we
performed a methylation interference analysis (27). Each
strand of the 45-bp oligonucleotide was labeled at the 5' end
using T4 polynucleotide kinase. The DNA was then partially
methylated on guanines with dimethyl sulfate and used as a
probe in the electrophoretic mobility shift assays as described
above. The DNA in complexes B1 and B2 (formed in binding
reactions containing nuclear extracts of Raji cells) and the
free DNA were isolated from the mobility shift gel, cleaved
with piperidine, and electrophoresed through a denaturing
polyacrylamide sequencing gel. If any of the methyl groups
introduced by dimethyl sulfate interfered with the binding of
a specific protein, then that molecule of DNA would be
selectively missing in the complex band and subsequently in
the corresponding guanine ladder. The results of this exper-
iment are shown in Fig. 6. In the 45-bp oligonucleotide,
methylation of the two guanine residues in the octamer
sequence interferes with DNA-protein interactions in B1 and
B2; no additional guanine residues appear to be involved in
complex formation. We conclude that the nuclear factors in
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FIG. 5. Binding competition analysis. As indicated above the
lanes, various unlabeled DNA fragments were used as competitors
in the electrophoretic mobility shift assay. These competitors were
added in the following amounts to binding reaction mixtures con-
taining as a probe -1 ng of labeled 45-bp oligonucleotide (lanes 1-6)
or -1 ng of labeled 50-bp oligonucleotide (lanes 7-12): 45 bp, 100 ng;
50 bp, 120 ng; 27 bp, unrelated sequence, 150 ng. Lanes 2 and 8,
nuclear extracts of HSB cells. Lanes 3-6 and lanes 9-12, nuclear
extracts of Raji cells. B1 and B2, positions ofcomplexes as described
in the legend to Fig. 4.
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FIG. 6. Methylation inter-
ference analysis of proteins
binding to the 45-bp oligonucle-
otide. DNA was 5' end-labeled
on either the coding or the
noncoding strand, partially
methylated with dimethyl sul-
fate, and incubated in binding
- W_ reaction mixtures with a Raji
_ _ _ cell nuclear extract. DNA from
complexes B1 and B2 (as de-
scribed in the legend to Fig. 4)
and free DNA (F) were isolated
from mobility shift gels,
cleaved with piperidine, and
electrophoresed through a 12%
polyacrylamide sequencing gel.
The arrows indicate the loca-
tions of two guanine residues at
which methylation specifically
interferes with protein binding.
ffi , As shown below the autoradi-
5 -ATT A T- 3 ograph, both of these guanine
3-T AAAC GTA-5 residues are located in the
octamer sequence.
DISCUSSION
DNA transfection is a useful functional assay for cis-acting
elements involved in the transcriptional regulation of genes.
Our gene transfer results indicate that DNA sequence infor-
mation sufficient for B-cell-specific expression of the HLA-
DRa gene is contained in a 140-bp promoter segment. This
DNA fragment includes class II boxes and an octamer
sequence, ATTTGCAT. This finding does not exclude the
possibility that additional cis-acting elements conferring
tissue specificity (such as an enhancer) are located elsewhere
in the DRa gene.
Using an electrophoretic mobility shift assay to identify
sequence-specific DNA-binding proteins, we have detected a
factor in nuclear extracts of human B-cell lines that binds to
an octamer-containing fragment of the DRa gene. Nuclear
extracts ofhuman T-cell lines and HeLa cells contain none or
very little of this factor. These findings are very similar, if not
identical, to reports of lymphoid-specific protein binding to
the octamer sequence in immunoglobulin genes. Staudt et al.
(27) describe a nuclear protein, NF-A2, that binds to the
octamer sequence in the immunoglobulin K-chain promoter
and that is found only in nuclear extracts of lymphoid cell
lines. Landolfi et al. (30) report a similar lymphoid-specific
protein that binds to the octamer sequence (inverted orien-
tation, ATGCAAAT) in the immunoglobulin heavy-chain
promoter. In contrast with our results, both of these groups
do detect the factor in nuclear extracts of T-cell lines. Both
reports suggest that the lymphoid-specific octamer-binding
protein accounts for the lymphoid-speciflic activity of immu-
noglobulin promoters. The protein that we describe may in a
similar fashion be involved in the tissue-specific expression
of the HLA-DRa gene and may be the hypothetical "trans-
acting factor" that regulates class II gene expression in B
cells (31, 32).
Ifthe octamer is an essential regulatory element in theDRa
gene promoter, one might predict that this sequence would be
found in a similar location in other class II genes. However,
Immunology: Sherman et al.
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when we searched for an octamer motif (ATTTGCAT or
ATGCAAAT) in all human and murine class II a- and p-chain
genes sequenced to date, no perfect homologies were detect-
ed. Seven of eight base-pair matches were found in the 5'
flanking regions of a DRB3 pseudogene (33), DC-3p8 (34), and
Ad (35). These octamer-like motifs were all located several
hundred base pairs upstream from the TATA boxes, much
further upstream than the octamers in the DRa and immu-
noglobulin promoters. A similar 7 of 8 bp matching sequence
is located -260 bp upstream from the TATA box in the
human invariant chain gene; this gene also contains class II
boxes (36).
Paradoxically, the octamer motif (ATTTGCAT, or the
inverse sequence, ATGCAAAT) is an essential element in a
variety of promoters that are not tissue-specific, including the
human histone 2B gene promoter (37), and human and
Xenopus U1 and U2 small nuclear RNA gene promoters
(38-41). Therefore, the lymphoid-specific activity of the
octamer motif in immunoglobulin genes and in HLA-DRa
does not result from the simple presence of this DNA
sequence in a promoter. In conflict with a report that a
synthetic promoter consisting of an octamer oligonucleotide
placed upstream of a TATA box is sufficient for lymphoid-
specific transcription (27), we observe no transcriptional
activity with a deletion mutant (5' A-53) in which the only
recognizable regulatory elements are the octamer and a
TATA box. Lymphoid specificity could nonetheless result
from the interaction of a lymphoid-specific protein with the
octamer in the promoters of the immunoglobulin and DRa
genes. In the histone 2B and small nuclear RNA genes,
factors distinct from this lymphoid-specific protein might
preferentially interact with the octamer to activate transcrip-
tion. Such differential binding of proteins to the same DNA
sequence is somewhat difficult to comprehend but may
involve interactions with additional regulatory factors. For
example, in the HLA-DRa gene promoter, factors binding to
the class II boxes could influence binding to the octamer
sequence. This hypothesis is supported by our transfection
data that indicate that at least the most 5' of the class II boxes
is required for DRa gene promoter function. A detailed
understanding of how the octamer element functions as a
transcriptional regulatory element may therefore require the
identification and purification of multiple, distinct, octamer-
specific DNA-binding proteins.
We observe one predominant DNA-protein complex when
we use a synthetic oligonucleotide containing both class II
boxes as a probe in the electrophoretic mobility shift assay.
No tissue-specific complexes are detected with this probe.
Further studies will be required to determine the relationship,
if any, of protein(s) that bind to the class II boxes to proteins
that bind to the octamer.
Note Added in Proof. Similar experiments with similar results have
been conducted in the laboratory of Donald Pious (personal com-
munication).
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